Have a feature idea you'd love to see implemented?
Let us know!
TERN Terns Pharmaceuticals Inc
Price (delayed)
$5.71
Market cap
$485M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.18
Enterprise value
$216.17M
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver
Highlights
TERN's equity has soared by 67% QoQ and by 41% YoY
Terns Pharmaceuticals's quick ratio has soared by 59% from the previous quarter and by 48% YoY
The company's EPS rose by 11% QoQ but it fell by 2.6% YoY
The net income is up by 8% since the previous quarter but it is down by 3.6% year-on-year
Terns Pharmaceuticals's debt has soared by 69% YoY
Key stats
What are the main financial stats of TERN
Market
Valuations
Earnings
Shares outstanding
84.94M
Market cap
$485M
Enterprise value
$216.17M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.1
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$87.8M
EBITDA
-$86.9M
Free cash flow
-$74.83M
Per share
Balance sheet
Liquidity
EPS
-$1.18
Free cash flow per share
-$0.96
Book value per share
$5.18
Revenue per share
$0
TBVPS
$4.86
Total assets
$378.23M
Total liabilities
$13.76M
Debt
$1.31M
Equity
$364.47M
Working capital
$365.09M
Debt to equity
0
Current ratio
32.99
Quick ratio
32.67
Net debt/EBITDA
3.09
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-31.3%
Return on equity
-32.8%
Return on invested capital
-60.8%
Return on capital employed
-23.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TERN stock price
How has the Terns Pharmaceuticals stock price performed over time
Intraday
1.96%
1 week
-12.82%
1 month
-21.13%
1 year
51.46%
YTD
-12.02%
QTD
-31.53%
Financial performance
How have Terns Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$99.98M
Net income
-$88.07M
Gross margin
N/A
Net margin
N/A
The net income is up by 8% since the previous quarter but it is down by 3.6% year-on-year
TERN's operating income is up by 8% since the previous quarter but it is down by 4.9% year-on-year
Growth
What is Terns Pharmaceuticals's growth rate over time
Valuation
What is Terns Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.1
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 11% QoQ but it fell by 2.6% YoY
TERN's equity has soared by 67% QoQ and by 41% YoY
The price to book (P/B) is 35% lower than the last 4 quarters average of 1.7
Efficiency
How efficient is Terns Pharmaceuticals business performance
TERN's ROIC is down by 19% YoY and by 12% from the previous quarter
The return on equity is up by 17% since the previous quarter but it has declined by 6% year-on-year
The company's return on assets rose by 17% QoQ but it fell by 6% YoY
Dividends
What is TERN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TERN.
Financial health
How did Terns Pharmaceuticals financials performed over time
The total assets has soared by 64% from the previous quarter and by 39% YoY
Terns Pharmaceuticals's quick ratio has soared by 59% from the previous quarter and by 48% YoY
Terns Pharmaceuticals's debt is 100% less than its equity
Terns Pharmaceuticals's debt has soared by 69% YoY
TERN's equity has soared by 67% QoQ and by 41% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.